Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | BAX | Q07812 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270983 | 0.96 | ALDH1A1 (0.62) | ALDH1A1HSD17B10GSTP1MAOANCOA1 | |
| SCHEMBL11135655 | 0.84 | IKBKB (0.60) | ALDH1A1HSD17B10NCOA1NCOA3LTA4H | |
| SCHEMBL2087211 | 0.82 | ALDH1A1 (0.57) | ALDH1A1HSD17B10GSTP1MAOANCOA1 | |
| SCHEMBL6480845 | 0.82 | ALDH1A1 (0.83) | ALDH1A1HSD17B10TSHRNPC1RAB9A | |
| SCHEMBL1578431 | 0.81 | MAOA (0.59) | ALDH1A1HSD17B10GSTP1MAOANCOA1 | |
| SCHEMBL16847542 | 0.81 | ALDH1A1 (0.60) | ALDH1A1HSD17B10GSTP1NCOA1NCOA3 | |
| Hydrogen Sulfide SCHEMBL27719824 | 0.80 | GSTP1 (0.63) | GSTP1MAOANCOA1NCOA3LTA4H | |
| SCHEMBL3786786 | 0.80 | MAOA (0.52) | ALDH1A1HSD17B10GSTP1MAOALTA4H | |
| SCHEMBL3784854 | 0.80 | GSTP1 (0.53) | ALDH1A1HSD17B10GSTP1MAOANCOA1 | |
| SCHEMBL3790623 | 0.80 | GSTP1 (0.53) | ALDH1A1HSD17B10GSTP1MAOANCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-9877962-B2 | Piperazinyl derivatives for the treatment of cancer | Pitty, Marc Henry (FR) | 2018-01-30 | — | — | US | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160237042-A1 | PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCER | PITTY, MARC HENRY (FR) | 2016-08-18 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885GSTP1 348/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885GSTP1 348/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885GSTP1 348/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885GSTP1 348/4885 |
| US-20160237042-A1 | PIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CANCER | NTPCR, MCL1, EP300 | ALDH1A1 226/4885HSD17B10 3264/4885GSTP1 405/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885GSTP1 348/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | ALDH1A1 2651/4885HSD17B10 1678/4885GSTP1 439/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885HSD17B10 1602/4885GSTP1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.